Anavex Posts Q3 Profit of $7.8M, Extends Cash Runway to FY2028
AVXL sits 32% above its 52-week low of $2.255.
Summary
Anavex reported Q3 FY2026 net income of $7.8M ($0.08 per share) and cash of $118.3M as of June 30, 2026, with management guiding a cash runway into mid-to-late FY2028. This is the first quarterly profit in recent memory and a sharp improvement from the $5.3M loss in Q2. The company also submitted Alzheimer's Phase 3 data to a new IND and initiated an ADME study, while Rett and Fragile X programs advance. The extended runway reduces near-term dilution risk, though the company still faces Nasdaq compliance, regulatory, and capital needs. The proxy fight with PVG Asset Management remains unresolved ahead of the September 24 shareholder vote.
At the time of this announcement, AVXL was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.2M. The 52-week trading range was $2.26 to $10.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.